OXFORD, U.K., 18th May 2026 – Re-Aim Therapeutics, an innovative biotechnology company developing functional cures for T cell-mediated autoimmune diseases, today announced its launch with a £7m Seed investment led by Syncona and Oxford Science Enterprises.
Re-Aim Therapeutics has been created to transform the standard of care for patients with autoimmune diseases by developing functional cures through the specific depletion of pathogenic T cells. Re-Aim’s proprietary discovery platform targets epitopes in their disease-relevant, functional state, enabling the development of therapeutics that can achieve selectivity unattainable through standard expression profiling. This enables improved efficacy and safety of depletion.
Re-Aim was founded in 2024 by Asher Maroof, PhD, a world-leading T cell immunologist with a deep understanding of pathogenic T cell subsets in autoimmune disease. The company’s lead asset, REA-001, is a novel monoclonal antibody that potently and selectively depletes pathogenic T cells implicated in a range of autoimmune diseases with high remaining unmet need.
“Our lead programme demonstrates highly efficacious depletion of type-17 T cells which are the causal pathogenic cell type coordinating and maintaining chronic inflammation across a range of autoimmune diseases,” said Asher Maroof, PhD, Chief Scientific Officer and Founder of Re-Aim. “By targeting cells only when they are in their functional state, we can achieve the selectivity necessary to safely harness the curative potential of cell depletion across all types of T cell-driven autoimmunity. Each programme in our pipeline has the potential to be positioned across numerous indications and enter markets projected to reach tens of billions of dollars in value.”
The Seed financing enables Re-Aim to advance its lead programme towards the clinic and build a pipeline of programmes spanning the breadth of autoimmune T cell-driven pathology by exploiting innovative, function-led approaches to drive enhanced selectivity.
“T cell-driven autoimmune diseases affect tens of millions of patients worldwide. Depletion of pathogenic subsets of T cells has the potential to drive transformational outcomes across a wide range of unmet needs. Re-Aim’s highly differentiated approach and compelling data position them as pioneers in this emerging field. I’m delighted to join the board as Chair and support them on their journey,” said Iain McGill.
“We believe accurate depletion of pathogenic cells can lead to immune reset and therefore full resolution of clinical symptoms in autoimmune diseases,” said Roel Bulthuis, Managing Partner at Syncona and Board Director at Re-Aim Therapeutics. “Syncona is excited to be supporting Re-Aim’s mission to deliver functional cures across a broad spectrum of autoimmune conditions.”
“Despite extensive innovation in the last 20 years, a significant number of autoimmune patients continue to show disease progression, or are treatment-refractory,” said Craig Fox, Operating Partner at Oxford Science Enterprises and Board Director at Re-Aim Therapeutics, said. “Functional cure for these devastating, chronic diseases has recently come into scope as a potentially transformative and widely accessible new approach. We are delighted to back Re-Aim’s world-class leadership and scientific team to advance the frontier of selective depletion of pathogenic T cells.”
The company’s leadership includes:
Re-Aim Therapeutics Executive Team
- Asher Maroof, PhD, Chief Scientific Officer and Founder, previously Head of Immunology Research and Translational Immunology at Exscientia and Head of Immune Reset and Research Lead for bimekizumab at UCB
- Alex Hamilton, PhD, Chief Financial Officer, previously an investor at Syncona and healthcare investment banker at Jefferies
Board of Directors
- Iain McGill, Chief Executive Officer, Quell Therapeutics
- Dhaval Patel, MD, PhD, Executive Vice President and Chief Scientific Officer, Sana Biotechnology
- Asher Maroof, PhD, Chief Scientific Officer and Founder, Re-Aim Therapeutics
- Roel Bulthuis, Managing Partner, Syncona
- Craig Fox, PhD, Operating Partner, Oxford Science Enterprises
- Pierre Joffrin, Senior Associate, Syncona
About Re-Aim Therapeutics
Re‑Aim Therapeutics is redefining how autoimmune diseases are treated by selectively depleting the pathogenic T cell subsets that drive chronic inflammation, autoimmunity and disease progression. By integrating human pathway signatures and transcription factor-linked membrane targets, we pinpoint the precise T cells coordinating and maintaining the autoimmune responses. By drugging precise target epitopes in their functional state and within the relevant disease context, we achieve a level of selectivity that conventional expression profiling and engineering approaches cannot reach. Our mission is to deliver functional cures across a broad spectrum of autoimmune conditions. We are a team with exceptional antibody discovery and development expertise, world‑class scientific advisors, and committed investors, all aligned around rigorous execution and transformative impact.